Amplification of the NUP214-ABL1 oncogene can be detected in patients with T cell acute lymphoblastic leukemia (T-ALL). We screened 29 patients with T cell malignancies for the expression of NUP214-ABL1 by reverse transcription-polymerase chain reaction (RT-PCR). NUP214-ABL1 was detected in three (10%) patients. These results were confirmed by fluorescence in situ hybridization techniques. We also studied the activity of imatinib, nilotinib and dasatinib against the human NUP214-ABL1-positive cell lines PEER and BE-13. All three tyrosine kinase inhibitors decreased the viability of PEER and BE-13 cells, but nilotinib and dasatinib had 41-log lower IC 50 values than imatinib (Po0.001). In contrast, the NUP214-ABL-negative T-ALL cell line Jurkat, was remarkably resistant to tyrosine kinase inhibition. The inhibition of cellular proliferation was associated with time-dependent induction of apoptosis and inhibition of ABL, CrKL and STAT5 phosphorylation. Moreover, dasatinib was active in a NUP214-ABL1-positive leukemia xenograft murine model and in marrow lymphoblasts from a patient with NUP214-ABL1-positive T-ALL. On the basis of these results, ABL1 kinase inhibitors warrant clinical investigation in patients with NUP214-ABL1-positive T-cell malignancies.
Introduction
The BCR-ABL1 oncogene encodes the constitutively active BCR-ABL1 tyrosine kinase encountered in most patients with chronic myeloid leukemia (CML) 1 and approximately one-third of patients with precursor B-cell acute lymphocytic leukemia (B-ALL). 2 In contrast, BCR-ABL1 has only been detected anecdotally in T-cell ALL (T-ALL). 3, 4 Amplification of the ABL1 gene in the absence of the BCR-ABL1 transcript was first reported in eight patients with T-ALL, appearing as multiple signals by fluorescence in situ hybridization (FISH). 5 Graux et al. 6 identified the formation of episomal structures resulting from the fusion between ABL1 and NUP214 as a novel mechanism of tyrosine kinase activation in cancer. The NUP214-ABL1 cryptic transcript was detected in five (5.8%) of 85 patients with T-ALL and in three of 22 T-ALL cell lines screened. 6 A more recent report has identified the presence of NUP214-ABL1 in 11 (3.9%) of 279 adult patients with T-ALL. 7 The current 5-year event-free survival rate for adult patients with ALL with modern chemotherapy regimens is only 40%. 2 Therapy with the ABL1 tyrosine kinase inhibitor (TKI) imatinib mesylate is associated with remarkable clinical activity in patients with CML. 8 The discovery of NUP214-ABL1 in T-ALL suggests a potential role for TKIs in the treatment of patients carrying this transcript. 6 TKIs with enhanced activity against ABL1 kinase and with the ability to override resistance mediated by most identified ABL1 kinase domain mutants have been developed. One such agent, nilotinib (formerly AMN107), binds ABL1 kinase in its inactive conformation, but exhibits 30-fold higher inhibitory activity than imatinib. 9 Dasatinib (formerly BMS-354825) has shown potent inhibitory activity against a variety of tyrosine kinases, including ABL1 and SRC family kinases. [10] [11] [12] Dasatinib binds ABL1 both in its active and inactive conformations, resulting in 1-and 2-log higher potency than nilotinib and imatinib, respectively. 11 Therapy with dasatinib has resulted in remarkable clinical activity in patients with CML in lymphoid blast phase or BCR-ABL1-positive B-ALL. 13 We investigated the frequency of the NUP214-ABL1 oncogene among a group of adult patients with T cell malignancies diagnosed at MD Anderson Cancer Center. Furthermore, we tested the sensitivity of NUP214-ABL1-positive human T-ALL cell lines to the TKIs imatinib, nilotinib and dasatinib. We documented that these compounds are active against NUP214-ABL1-positive T cells, but differ with regard to their ability to inhibit NUP214-ABL1 kinase and induce apoptosis. These results provide the rationale for the incorporation of TKIs into current chemotherapy regimens for the treatment of patients with NUP214-ABL1-positive T-ALL.
Materials and methods

Reagents and antibodies
Imatinib and nilotinib were provided by Novartis (East Hanover, NJ, USA) and dasatinib was provided by Bristol-Myers Squibb Oncology (Princeton, NJ, USA). All drugs were stored at -20 1C as a 10 mM stock solution in dimethyl sulfoxide (DMSO). Antibodies and their sources were as shown in Supplementary Information.
Cell culture and clinical samples
Three NUP214-ABL1-positive (SIL-ALL, PEER, BE-13) 6 and two NUP214-ABL1-negative (Jurkat, HPB-ALL) cell lines were employed. PEER and Jurkat cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). SIL-ALL, BE-13 and HPB-ALL were purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany). Although PEER and BE-13 show identical DNA fingerprints, PEER cells feature a pseudodiploid karyotype whereas BE-13 is tetraploid.
14,15 All T-ALL cell lines and human bone marrow (BM) cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 100 U ml À1 penicillin G and 100 mg ml À1 streptomycin at 37 1C under 5% CO 2 . BM and peripheral blood samples at diagnosis were available from 29 of 129 patients with T-cell malignancies registered in the Department of Leukemia tissue bank at MDACC. The research protocol was approved by the Institutional Review Board at MDACC.
Reverse transcriptase-PCR analysis of NUP214-ABL1 transcripts and expression of CDKN2A, CDKN2B, TLX1 and TLX3
RNA was extracted using TRIzol reagents (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed into cDNA using the SuperScript First-Strand Synthesis System kit for RT-PCR (Invitrogen). Then, cDNA was amplified using the primers NUP23 (exon 23), NUP29 (exon 29), NUP31 (exon 31) and NUP32 (exon 32), NUP34 (exon34), combined with ABL1-R1 primer. Molecular screening for CDKN2A, CDKN2B, TLX1 and TLX3 was carried out. Conditions and primers are shown in Supplementary Information.
Fluorescence in situ hybridization
To detect NUP214-ABL1 by FISH, one bacterial artificial chromosome (BAC) clone which overlaps NUP214 (RP11-544A12; 132,960-133,150 KB on chromosome 9q) and one clone that overlaps ABL1 (RP11-83J21; 132,640-132,820 KB on chromosome 9q) were selected using mapping information from the National Center of Biotechnology Information. 16 DNA extracted from one BAC clone was labeled using digoxigenin-11-UTP or biotin-UTP by nick translation and detected with anti-digoxigenin-rhodamine (red) or avidin-FITC (green) fragments (Supplementary Information).
Cell proliferation and cell cycle assays
Exponentially growing T-ALL cell lines were plated at 1 Â 10 4 cells per well in 96-well plates in RPMI-1640 medium supplemented with 10% FCS. TKIs were included in media at increasing concentrations. Viable cell number was assessed 72 h postplating by the three methanethiosulfonate-based viability assay (CellTiter 96 Aqueous One Solution Reagent, Promega Corporation, Madison, WI, USA) as described. 17 Apoptosis was determined by annexin V positivity detected by flow cytometry as previously described. 18 All experiments were performed in triplicate.
Western blot analysis
Control cells and cells treated with the test TKIs were subjected to protein extraction. Antibodies were added to aliquots of lysates. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting were previously described.
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NUP214-ABL1-positive leukemia xenograft murine model ALL-SIL cells or HPB-ALL were suspended (2 Â 10 8 cells ml À1 ) in RPMI-1640 medium. In all 0.1 ml of the suspension was injected subcutaneously into the ventral axillary region of female NOD/ SCID mice (Harlan, IN, USA). Tumors were staged to a mass of 150-300 mg and animals were evenly distributed to various treatment and control groups (eight mice per group). For administration to mice, dasatinib was dissolved in a mixture of propylene glycol/water (50:50). Animals were treated with dasatinib or placebo 0.01 ml gm À1 of mice every 24 h by oral gavage. Tumor response was determined two times weekly by measurement of tumors with a caliper until they reached a target size of 1 g. Tumor weight was estimated from the formula: Tumor weight ¼ (length Â width 2 )C2.
Results
Frequency of NUP214-ABL1 transcript in patients with T cell malignancies
We screened 29 patients, 23 with T-ALL and six with T-lymphoblastic lymphoma, for the presence of NUP214-ABL1. Three (10%) patients were found to carry 
Characteristics and outcome of the NUP214-ABL1-positive patients
No significant differences were observed at diagnosis between NUP214-ABL1-positive and -negative patients, except for a lower marrow blast percentage in patients expressing NUP214-ABL1 (Supplementary Table 1 ), as two of these three patients had T-lymphoblastic lymphoma (T-LL). Patient 1 was diagnosed with precursor T-ALL and presented with leukemia cutis, whereas Patients 2 and 3 were presented with a mediastinal mass and were diagnosed with precursor T-LL. All patients received hyperCVAD chemotherapy. 20 Patients 2 and 3 received additional mediastinal radiotherapy. Patient 1 achieved a complete remission (CR) after two cycles of hyperCVAD but expired due to mediastinal and leptomeningeal relapse after six cycles of chemotherapy. Patient 3 expired in CR after nine cycles of hyperCVAD due to pneumocystis jiroveci pneumonia. Patient 2 achieved a CR after the first cycle of hyperCVAD, continued therapy for a total of eight cycles, and is currently receiving maintenance POMP chemotherapy (mercaptopurine, methotrexate, vincristine and prednisone). No significant differences were observed regarding survival between NUP214-ABL1-positive and -negative patients (Supplementary Figure 1) .
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Imatinib, nilotinib and dasatinib inhibit the proliferation of NUP214-ABL1-positive cells in vitro
NUP214-ABL1-positive cell lines are ideal models to study the sensitivity of the NUP214-ABL1 kinase to TKIs. Preliminary results suggested that imatinib was active against the SIL-ALL cell line. 6 We exposed PEER and BE-13 cells to increasing concentrations of imatinib, nilotinib and dasatinib up to 10 mM. PEER cell viability was significantly reduced after 72 h of treatment with all three TKIs (Figure 2) . However, the IC 50 was almost 10-fold higher for imatinib (643 nM) than for nilotinib (68 nM) or dasatinib (IC 50 39 nM) (Po0.001) (Figures 2a-c) . This is consistent with the higher in vitro activity of nilotinib (IC 50 25 nM) 9 and dasatinib (IC 50 1 nM) 11 compared with imatinib (IC 50 100-500 nM) 20, 21 in BCR-ABL1-positive cells. BE-13 cells proved slightly less sensitive to these TKIs than PEER cells (Figures 2d-f) . The NUP214-ABL1-negative T-ALL cell line Jurkat was remarkably resistant to TKIs (IC 50 not reached) (Figures 2g-i) , indicating that the cytotoxicity induced by these compounds is not related to a general toxic effect on T-ALL cell lines. Interestingly, SIL-ALL cells were highly sensitive to dasatinib with IC 50 values of 0.65 nM (Supplementary Figure 2) .
Imatinib, nilotinib and dasatinib induce apoptosis in NUP214-ABL1-positive cells
We next analyzed whether the ability of imatinib, nilotinib and dasatinib to inhibit the growth of NUP214-ABL1-positive cells was associated with induction of apoptosis. By flow cytometry, the percentage of annexin V-positive cells increased in a timeand dose-dependent manner after treatment with all three TKIs at their respective IC 50 concentrations, indicating apoptotic cell death. After exposure for 48 h, and as expected based on cell proliferation assays, apoptosis was more pronounced in PEER and BE-13 cells treated with dasatinib relative to those exposed to imatinib or nilotinib (Figures 3a and b) . Exposure of PEER cells to increasing concentrations of dasatinib for 48 h led to enhanced accumulation of PEER cells in the sub-G1 cell cycle phase, indicating DNA fragmentation and degradation, which is an early event in the apoptotic process (Figure 3c ). Similar data were obtained in BE-13 cells (data not shown). Treatment of PEER cells with nilotinib or dasatinib at 50 or 100 nM resulted in significant cleavage of PARP (85 kDa fragment) after 24 h of treatment and time-dependent proteolytic activation of caspase-3 and caspase-9, which are responsible for the activation of key proteins involved in the caspase cascade leading to apoptosis. Exposure to both compounds also resulted in diminished levels of the antiapoptotic protein BCL-2, particularly after 48 h of treatment with dasatinib 100 nM (Figure 4 ).
Imatinib and nilotinib inhibit CrKL phosphorylation in NUP214-ABL1-positive cells
Next, we investigated the activity of TKIs against signaling elements downstream of NUP214-ABL1 kinase. To this end, we exposed PEER cells to escalating concentrations of imatinib or nilotinib for 3 h. Nilotinib is structurally related to imatinib but has 30-fold higher potency against ABL1 kinase. CrKL is an SH2 (SRC homology domain)/SH3-containing adapter protein that is a direct target of ABL1 kinase. [22] [23] [24] CrKL couples nonreceptor tyrosine kinases to downstream signaling cascades that regulate gene expression 25 and is regarded as a surrogate of ABL1 kinase activation. 26 Exposure of PEER cells to increasing concentrations of imatinib and nilotinib for 3 h resulted in inhibition of CrKL phosphorylation, but this was more pronounced upon nilotinib exposure (Figure 5a ). Exposure to escalating concentrations of either TKI did not affect significantly the expression of the NUP214 protein. Altogether, these results suggest that ABL1 kinase is a direct target of TKIs in NUP214-ABL1-positive leukemic cells. Since dasatinib and nilotinib are significantly more potent than imatinib against ABL1 kinase, 9,11 we compared directly the inhibitory activity of these TKIs against NUP214-ABL1-positive cells. Exposure of PEER cells to increasing concentrations of both TKIs (range, 1-100 nM) for 3 h led to reduced ABL1 phosphorylation (Figure 5b ). ABL1 phosphorylation was detected with specific antibodies against Tyr245, which is located in the linker region between the SH2 and the catalytic domains. Phosphorylation of this residue is important for the activation of ABL1 kinase activity. 27 However, we could not demonstrate phosphorylation at Tyr412 (data not shown), mapping to the kinase activation loop of ABL1, whose phosphorylation is also required for ABL1 kinase activity. When the membrane was stripped and reprobed with anti-ABL1 antibody, the amount of total ABL1 remained unchanged, indicating that imatinib and nilotinib abolished ABL1 phosphorylation without altering ABL1 expression (Figure 5b ). Nilotinib and dasatinib also reduced dramatically CrKL phosphorylation. However, dasatinib concentrations as low as 10 nM resulted in complete abrogation of CrKL phosphorylation, an effect that could not be observed with concentrations of nilotinib up to 100 nM. This is in concert with the 1-log higher activity of dasatinib against ABL kinase.
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Moreover, the phosphorylation of STAT5, a downstream target of ABL1 kinase and a recurrent theme in cellular transformation by oncogenic kinases, was also inhibited by both, nilotinib and dasatinib. The inhibition of CrKL and STAT5 phosphorylation was time-dependent (data not shown). Because the inhibition of phosphorylation of CrKL and STAT5 antedated the induction of apoptosis in PEER cells, it is likely that the former events contribute to the proapoptotic effect of these TKIs in NUP214-ABL1-positive cells.
In vivo and ex vivo effect of TKIs on NUP214-ABL1-positive T-ALL cells
Next, we tested the activity of dasatinib in a NUP214-ABL1-positive T-ALL xenograft mouse model. Administration of dasatinib to mice resulted in remarkable growth inhibition of SIL-ALL tumors after 19 days of treatment compared with control animals treated with placebo (1085 vs 3236 mg; P ¼ 0.02) (Figure 6a ). However, dasatinib did not impact significantly the growth of T-ALL xenografts derived from NUP214-ABL1-negative HPB-ALL cells compared to placebo (Figure 6b Treatment with either TKI decreased the levels of the proapoptotic protein BCL-2 after 24 h, but this effect was more pronounced with dasatinib. After 48 h, dasatinib 100 nM resulted in undetectable levels of BCL-2.
Imatinib, nilotinib and dasatinib inhibit NUP214-ABL1-positive cells A Quintás-Cardama et al an equipotent concentration of dasatinib (Figure 6d ). In contrast, samples from patients with NUP214-ABL1-negative T-ALL did not show significant CrKL or STAT5 phosphorylation (Figure 6d ). These results indicate that NUP214-ABL1 tyrosine kinase is constitutively activated in vivo and that inhibition of its activation by potent ABL1 TKIs such as nilotinib or dasatinib results in dramatic abrogation of proliferation of cells carrying this oncogenic fusion kinase.
Discussion
The NUP214-ABL1 fusion transcript has been described in 3.9-5.8% of patients with T-ALL. 6, 7 In our series, three of 29 screened patients were found to carry the NUP214-ABL1 transcript by RT-PCR and FISH, with excellent concordance between both techniques. Although NUP214-ABL1-positive patients, particularly those overexpressing the transcription factor TLX3 (HOX11L2), 28 had been initially linked to a poorer outcome, 6 data from a cohort of 279 adult patients with T-ALL treated with the German multicenter adult ALL trials, 7 do not support a difference in overall survival between NUP214-ABL1-positive and -negative patients.
The discovery of NUP214-ABL16 emphasizes the genetic heterogeneity of T-ALL, but more importantly, unveils new opportunities for targeted therapy. Our experiments show that imatinib, nilotinib and dasatinib inhibit the growth of the NUP214-ABL1-positive PEER, BE-13 and SIL-ALL cells, with nilotinib and dasatinib exhibiting 41-log higher antiproliferative activity than imatinib against PEER and BE-13. Dasatinib completely abrogated CrKL and STAT5 phosphorylation in PEER cells, and these events antedated the proteolytic activation of caspase-3 and caspase-9, and BCL-2 downregulation, suggesting that abrogation of CrKL and STAT5 activation may be responsible for the proapoptotic effect of TKIs in NUP214-ABL1-positive cells. More important, the potent activity in vitro of dasatinib was recapitulated in a xenograft murine model of NUP214-ABL1-positive T-ALL and in lymphoblasts obtained from a patient with NUP214-ABL1-positive T-ALL. Currently, combinations of cytotoxic agents with TKIs constitute the In this setting, a combination of dasatinib with steroids as frontline has been recently reported to be highly effective and safe. On the basis of these data and on the results herein presented, it is reasonable to hypothesize that the therapy with potent ABL1 TKIs hold promise for the treatment of patients with T-ALL expressing NUP214-ABL1 kinase. Several aspects of the biology of NUP214-ABL1-positive leukemia remain unexplained. First, we have been unable to demonstrate phosphorylation of Tyr412 in the activation loop of NUP214-ABL1, which regulates directly the catalytic activity of ABL1 kinase and increases the latter by about ninefold. 27 However, we detected phosphorylation of Tyr245, but this was faint and in BCR-ABL1-positive cells it only stimulates ABL1 kinase activity about 2.5-fold. 27 This suggests that NUP214-ABL1 per se induces relatively weak proliferative effects. This is further supported by the fact that Ba/F3 cells transduced with NUP214-ABL1 warrant longer periods of time to reach the same proliferation level as Ba/F3 cells transformed by BCR-ABL1. 29 However, PEER and BE-13 cells exhibited lower sensitivity to imatinib, nilotinib and dasatinib relative to BCR-ABL1-positive cells, suggesting that the suboptimal kinase activity of NUP214-ABL1 is circumvented by alternate mechanisms (for example, NUP214-ABL1 amplification). Second, although NUP214-ABL1 kinase may be sufficient to induce cell proliferation, additional mutations are likely to be required to induce leukemia. As in the present report, NUP214-ABL1 has been frequently associated with overexpression of the homeobox genes TLX1 (HOX11) 6, 7 or TLX3 (HOX11L2) 6, 7, 28 and/or deletion of the tumor suppression genes CDKN2A and CDKN2B (p15). 6 The interplay between all these mutations and NUP214-ABL1 remains largely unknown. Finally, NUP214 is a phenylalanine-glycine (FG)-containing cytoplasmic-oriented nuclear pore complex protein implicated in nucleocytoplasmic transport. 30 Whether the intrinsic leukemogenic potential of NUP214-ABL1 kinase is additionally implemented by impairment of nucleocytoplasmic transport or through interaction with other nuclear pore proteins warrants further investigation.
To conclude, NUP214-ABL1 expression can be readily detected by PCR and FISH techniques, which represent valuable tools for diagnosis and monitoring of residual disease. More important, NUP214-ABL1 renders a subset of patients with T cell malignancies amenable to TKI therapy. Among the TKIs tested in this study, nilotinib, and particularly dasatinib, showed significantly higher antiproliferative activity than imatinib in vitro. This provides the rationale for the integration of these agents into chemotherapeutic schemes currently employed in the treatment of patients with T-ALL. Imatinib, nilotinib and dasatinib inhibit NUP214-ABL1-positive cells A Quintás-Cardama et al
